Carcelli Mauro, Rogolino Dominga, Gatti Anna, Pala Nicolino, Corona Angela, Caredda Alessia, Tramontano Enzo, Pannecouque Christophe, Naesens Lieve, Esposito Francesca
Department of Chemistry, University of Parma Parma, Italy.
Department of Chemistry, University of ParmaParma, Italy; Research Interuniversity Consortium Chemistry of Metals in Biological Systems Parma Unit, University of ParmaParma, Italy.
Front Microbiol. 2017 Mar 20;8:440. doi: 10.3389/fmicb.2017.00440. eCollection 2017.
Human immunodeficiency virus type 1 (HIV-1) infection, still represent a serious global health emergency. The chronic toxicity derived from the current anti-retroviral therapy limits the prolonged use of several antiretroviral agents, continuously requiring the discovery of new antiviral agents with innovative strategies of action. In particular, the development of single molecules targeting two proteins (dual inhibitors) is one of the current main goals in drug discovery. In this contest, metal-chelating molecules have been extensively explored as potential inhibitors of viral metal-dependent enzymes, resulting in some important classes of antiviral agents. Inhibition of HIV Integrase (IN) is, in this sense, paradigmatic. HIV-1 IN and Reverse Transcriptase-associated Ribonuclease H (RNase H) active sites show structural homologies, with the presence of two Mg(II) cofactors, hence it seems possible to inhibit both enzymes by means of chelating ligands with analogous structural features. Here we present a series of -acylhydrazone ligands with groups able to chelate the Mg(II) hard Lewis acid ions in the active sites of both the enzymes, resulting in dual inhibitors with micromolar and even nanomolar activities. The most interesting identified -acylhydrazone analog, compound , shows dual RNase H-IN inhibition and it is also able to inhibit viral replication in cell-based antiviral assays in the low micromolar range. Computational modeling studies were also conducted to explore the binding attitudes of some model ligands within the active site of both the enzymes.
1型人类免疫缺陷病毒(HIV-1)感染仍是全球严重的健康紧急情况。当前抗逆转录病毒疗法产生的慢性毒性限制了几种抗逆转录病毒药物的长期使用,因此持续需要发现具有创新作用策略的新型抗病毒药物。特别是,开发靶向两种蛋白质的单分子(双重抑制剂)是当前药物研发的主要目标之一。在这种情况下,金属螯合分子已被广泛探索作为病毒金属依赖性酶的潜在抑制剂,从而产生了一些重要类别的抗病毒药物。从这个意义上讲,抑制HIV整合酶(IN)具有代表性。HIV-1整合酶和逆转录酶相关核糖核酸酶H(RNase H)的活性位点显示出结构同源性,都存在两个Mg(II)辅因子,因此似乎可以通过具有类似结构特征的螯合配体来抑制这两种酶。在此,我们展示了一系列具有能够螯合这两种酶活性位点中Mg(II)硬路易斯酸离子基团的酰腙配体,从而产生具有微摩尔甚至纳摩尔活性的双重抑制剂。最有趣的已鉴定酰腙类似物化合物,显示出对RNase H和整合酶的双重抑制作用,并且在低微摩尔范围内还能够在基于细胞的抗病毒试验中抑制病毒复制。还进行了计算建模研究,以探索一些模型配体在这两种酶活性位点内的结合态势。